Biosimilar infliximab for inflammatory bowel disease: from concepts to clinical practice. Case study illustrated with CT-P13
出版年份 2015 全文链接
标题
Biosimilar infliximab for inflammatory bowel disease: from concepts to clinical practice. Case study illustrated with CT-P13
作者
关键词
-
出版物
Expert Review of Gastroenterology & Hepatology
Volume 9, Issue sup1, Pages 5-15
出版商
Informa UK Limited
发表日期
2015-09-23
DOI
10.1586/17474124.2015.1091304
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- NCCN Biosimilars White Paper: Regulatory, Scientific, and Patient Safety Perspectives
- (2017) Andrew D. Zelenetz et al. Journal of the National Comprehensive Cancer Network
- The epidemiology of inflammatory bowel disease
- (2015) Johan Burisch et al. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY
- OP0068 A Phase 3 Randomised Controlled Trial to Compare CT-P13 with Infliximab in Patients with Active Rheumatoid Arthritis: 54 Week Results from the Planetra Study
- (2014) D. H. Yoo et al. ANNALS OF THE RHEUMATIC DISEASES
- FRI0421 A randomised, double-blind, parallel-group, phase 1 study comparing the pharmacokinetics, safety and efficacy of ct-p13 and infliximab in patients with active ankylosing spondylitis: 54 week results from the planetas study
- (2014) W. Park et al. ANNALS OF THE RHEUMATIC DISEASES
- A Review of CT-P13: An Infliximab Biosimilar
- (2014) Kate McKeage BIODRUGS
- The challenge of indication extrapolation for infliximab biosimilars
- (2014) Brian G. Feagan et al. BIOLOGICALS
- Biosimilars: the science of extrapolation
- (2014) M. Weise et al. BLOOD
- Physicochemical characterization of Remsima®
- (2014) Soon Kwan Jung et al. mAbs
- Biopharmaceutical benchmarks 2014
- (2014) Gary Walsh NATURE BIOTECHNOLOGY
- Review article: biosimilars are the next generation of drugs for liver and gastrointestinal diseases
- (2013) M. Rinaudo-Gaujous et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Biosimilars in rheumatology: the wind of change
- (2013) Christian K Schneider ANNALS OF THE RHEUMATIC DISEASES
- A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study
- (2013) Dae Hyun Yoo et al. ANNALS OF THE RHEUMATIC DISEASES
- A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study
- (2013) Won Park et al. ANNALS OF THE RHEUMATIC DISEASES
- Late-Breaking Abstracts
- (2013) ARTHRITIS AND RHEUMATISM
- Biosimilar monoclonal antibodies: a science-based regulatory challenge
- (2013) Paul J Declerck EXPERT OPINION ON BIOLOGICAL THERAPY
- Biosimilar Safety Considerations in Clinical Practice
- (2013) Edwin Choy et al. SEMINARS IN ONCOLOGY
- The role of biosimilars in the treatment of rheumatic diseases
- (2012) Thomas Dörner et al. ANNALS OF THE RHEUMATIC DISEASES
- Biosimilars: what clinicians should know
- (2012) M. Weise et al. BLOOD
- Biosimilars: Impact of Biologic Product Life Cycle and European Experience on the Regulatory Trajectory in the United States
- (2012) Islah Ahmed et al. CLINICAL THERAPEUTICS
- Comparability and biosimilarity: considerations for the healthcare provider
- (2012) Jaymi F. Lee et al. CURRENT MEDICAL RESEARCH AND OPINION
- The safety of switching between therapeutic proteins
- (2012) Hans C Ebbers et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Interchangeability, immunogenicity and biosimilars
- (2012) Hans C Ebbers et al. NATURE BIOTECHNOLOGY
- Increasing Incidence and Prevalence of the Inflammatory Bowel Diseases With Time, Based on Systematic Review
- (2011) Natalie A. Molodecky et al. GASTROENTEROLOGY
- Key concepts and critical issues on epoetin and filgrastim biosimilars. A position paper from the Italian Society of Hematology, Italian Society of Experimental Hematology, and Italian Group for Bone Marrow Transplantation
- (2011) G. Barosi et al. HAEMATOLOGICA
- Concerns about the use of biosimilar granulocyte colony-stimulating factors for the mobilization of stem cells in normal donors: position of the World Marrow Donor Association
- (2011) B. E. Shaw et al. HAEMATOLOGICA
- Acceptable changes in quality attributes of glycosylated biopharmaceuticals
- (2011) Martin Schiestl et al. NATURE BIOTECHNOLOGY
- Biosimilars—why terminology matters
- (2011) Martina Weise et al. NATURE BIOTECHNOLOGY
- Tungsten-Induced Denaturation and Aggregation of Epoetin Alfa During Primary Packaging as a Cause of Immunogenicity
- (2011) Andreas Seidl et al. PHARMACEUTICAL RESEARCH
- Production of therapeutic antibodies with controlled fucosylation
- (2010) Naoko Yamane-Ohnuki et al. mAbs
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started